Obesity - Important Risk Factor for Sleep Apnea Syndrome

Sleep apnea syndrome is a common pathology with negative consequences on cardiovascular and metabolic diseases. The relationship between obesity and OSAS is complex, multifactorial and bidirectional; that leads to a negative mutual influence of the two pathologies. The main purpose of this study is to evaluate the risk associated with obesity and the occurrence of the apnea phenomenon, as well as, to compare the various polysomnographic parameters and to compare them with obesity. 100 patients took part to this study. 60 % of the patients were diagnosed with OSAS. 71 % of the patients had varying degrees of obesity. Significant statistic differences were revealed between: the Mean variation of the BMI in patients with and without apnea (T Test p= 0,007 < 0,05); the dorsal AHI Mean of the non-obese group as against to the dorsal AHI Mean of the obese group (T Test p= 0,002), the AHI Mean in other positions of the non-obese group as against to the AHI Mean in other positions of the obese group (T Test p= 0,000) and the Mean of the arousal index of the non-obese group as against to the Mean of the arousal index of the obese group (T Test p= 0,009). The current study revealed that the arousals associated with breathing events and the position during sleep, especially in obese patients, worsen the consequences of OSAS

The Main Symptoms in Dorsal Sleep Apnea - Hypopnea Syndrome

OSAHS is a chronic, multifactorial disease, accompanied by significant and complex symptoms. The aim of this study was to evaluate the relationship between OSAHS and dorsal AHI in order to improve early diagnosis of dorsal sleep apnea-hypopnea syndrome. There were significant statistical differences between: the dorsal AHI Mean of the group without excessive daytime sleepiness as opposed to the dorsal AHI Mean of the group with excessive daytime sleepiness; the dorsal AHI Mean of the group without snoring as opposed to the dorsal AHI Mean of the group with snoring; the dorsal AHI Mean of the group without restless sleep as opposed to the dorsal AHI Mean of the group with restless sleep; the dorsal AHI Mean of the group without dyspnea as opposed to the dorsal AHI Mean of the group with dyspnea; the dorsal AHI Mean of the group without night sweats as opposed to the dorsal AHI Mean of the group with night sweats; the dorsal AHI Mean of the group without irritability as opposed to the dorsal AHI Mean of the group with irritability and the dorsal AHI Mean of the group without nightmares as opposed to the dorsal AHI Mean of the group with nightmares. Through this study we highlighted that excessive daytime sleepiness and snoring are prevalent symptoms in dorsal OSAHS. The presence of these symptoms in patients with sleep disorders may improve early diagnosis and the choice of an appropriate treatment for dorsal sleep apnea- hypopnea syndrome, thus participating in improving the patient’s life qualit

Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study

International audienceBackground Response Evaluation Criteria in Solid Tumors (RECIST) are widely used to assess the effect of chemotherapy in patients with cancer. We hypothesised that the change in unidimensional tumour size handled as a continuous variable was more reliable than RECIST in predicting overall survival (OS). Methods The prospective Pharmacogenoscan study enrolled consecutive patients with non-small-cell lung cancer (NSCLC) at any stage seen between 2005 and 2010 at six hospitals in France, given chemotherapy. After exclusion of patients without RECIST or continuous-scale tumour size data and of those with early death, 464 patients were left for the survival analyses. Cox models were built to assess relationships between RECIST 1.1 categories or change in continuous-scale tumour size and OS. The best model was defined as the model minimising the Akaike Information Criterion (AIC). Results OS was 14.2 months (IQR, 7.3-28.9 months). According to RECIST 1.1, 146 (31%) patients had a partial or complete response, 245 (53%) stable disease, and73 (16%) disease progression. RECIST 1.1 predicted better OS than continuous-scale tumour in early (Conclusion In this large observational study, change in continuous-scale tumour size did not perform better than RECIST 1.1 in predicting survival of patients given chemotherapy to treat NSCLC